Last reviewed · How we verify

Placebo to V260 — Competitive Intelligence Brief

Placebo to V260 (Placebo to V260) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

phase 3 Immunology Biologic Live · refreshed every 30 min

Target snapshot

Placebo to V260 (Placebo to V260) — Merck Sharp & Dohme LLC. V260 is an investigational vaccine candidate designed to elicit immune responses against a specific target antigen.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo to V260 TARGET Placebo to V260 Merck Sharp & Dohme LLC phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to V260 — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-v260. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: